Sun Pharma Advanced Research Company Limited — Updates, 17-12-2024: Press Release

SPARC has signed a binding Letter of Intent with UCSF and Tiller Therapeutics to license its rights to a pre-clinical oncology asset and associated intellectual property. This agreement, developed over a three-year partnership, grants SPARC a 55% equity stake in Tiller Therapeutics. The equity will vest in two stages: 45% upon the execution of the license agreement, and the remaining 10% will vest based on the achievement of milestones or within six months of the agreement's execution.

This strategic move underscores SPARC's commitment to advancing treatments for solid tumors, potentially addressing a significant unmet medical need. With the licensing deal, SPARC strengthens its pipeline while aligning with Tiller's mission in oncology, leading to promising growth opportunities ahead. Investors should monitor this partnership closely, as it may enhance SPARC's market position and stimulate future revenue growth.